<DOC>
	<DOCNO>NCT01286142</DOCNO>
	<brief_summary>In June 2009 , World Health Organization ( WHO ) declare global pandemic influenza A ( H1N1 ) . Although little known pandemic influenza strain child , previous pandemic influenza season child less one year age show high risk influenza complication old child . In light 2009 H1N1 pandemic situation , U.S. Food Drug Administration ( FDA ) , European Medicines Agency ( EMA ) , Health Canada issue emergency authorization oseltamivir use treat prevent influenza infant 1 year age . It anticipate oseltamivir use infant dramatically increase due new authorization use population high prevalence H1N1 influenza circulate population . Ongoing safety surveillance critical study provide data evaluate risk/benefit ratio prescribe oseltamivir population current milieu seasonal pandemic influenza virus circulate population . The study also provide useful information dose duration treatment use clinical practice relationship adverse event .</brief_summary>
	<brief_title>Oseltamivir Infant Influenza Safety Study</brief_title>
	<detailed_description>This study prospective , observational , multicenter short-term safety study use oseltamivir ( prophylaxis treatment ) child 24 month age young . An internal comparator group child diagnose influenza treat antiviral medication enrol . The study include 30-day follow-up period conduct multiple site multiple country within European Union . The study cover two consecutive influenza season : 01 October 2009 - 31 May 2010 01 October 2010 - 31 May 2011 . Data collection may interrupt interim period influenza season ( June 1 , 2010 - September 30 , 2010 ) , depend whether influenza season follow expect cycle .</detailed_description>
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Oseltamivir</mesh_term>
	<criteria>24 month age young time enrollment Diagnosis influenza A B ( suspected* confirm viral testing ) either treat oseltamivir antiviral OR prescribe oseltamivir postexposure influenza prophylaxis Parent/legal guardian willing provide inform consent contact telephone part followup Patients exclude treat influenza antiviral oseltamivir , include amantadine , rimantadine , zanamivir . Suspected influenza define acute febrile illness characterize presence fever 1 follow symptom : cough , coryza/nasal congestion sore throat .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>24 Months</maximum_age>
	<verification_date>October 2011</verification_date>
	<keyword>Prospective , Observational Safety Study</keyword>
</DOC>